Now you can ask whether any of the standard anti-tuberculosis treatments exhibit the pharmacokinetic mismatch problem. This figure shows data for rifater, a common three-drug anti-tuberculosis agent. What you see is that isoniazid will tend to be above its MIC alone for more than a third of the dosing time. A combination of patient noncompliance, HIV disease, and pharmacokinetic mismatch may contribute to the increasing frequency of INH-resistance.

Go to Comment Form